You are here
High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life.
Thursday,2024-07-11 11:38 America/Los_Angeles — ecterry
| Title | High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life. |
| Publication Type | Journal Article |
| Year of Publication | 2024 |
| Authors | Ramonfaur, D, Buckley, LF, Arthur, V, Yang, Y, Claggett, BL, Ndumele, CE, Walker, KA, Austin, T, Odden, MC, Floyd, JS, van Wijk, SSanders-, Njoroge, J, Kizer, JR, Kitzman, D, Konety, SH, Schrack, J, Liu, F, B Windham, G, Palta, P, Coresh, J, Yu, B, Shah, AM |
| Journal | JAMA Cardiol |
| Volume | 9 |
| Issue | 7 |
| Pagination | 649-658 |
| Date Published | 2024 Jul 01 |
| ISSN | 2380-6591 |
| Keywords | Aged, Biomarkers, Female, Frailty, Heart Failure, Humans, Incidence, Male, Middle Aged, Proteomics, Risk Factors |
| Abstract | <p><b>IMPORTANCE: </b>Heart failure (HF) and frailty frequently coexist and may share a common pathobiology, although the underlying mechanisms remain unclear. Understanding these mechanisms may provide guidance for preventing and treating both conditions.</p><p><b>OBJECTIVE: </b>To identify shared pathways between incident HF and frailty in late life using large-scale proteomics.</p><p><b>DESIGN, SETTING, AND PARTICIPANTS: </b>In this cohort study, 4877 aptamers (Somascan v4) were measured among participants in the community-based longitudinal Atherosclerosis Risk In Communities (ARIC) cohort study at visit 3 (V3; 1993-1995; n = 10 638) and at visit 5 (V5; 2011-2013; n = 3908). Analyses were externally replicated among 3189 participants in the Cardiovascular Health Study (CHS). Data analysis was conducted from February 2022 to June 2023.</p><p><b>EXPOSURES: </b>Protein aptamers, measured at study V3 and V5.</p><p><b>MAIN OUTCOMES AND MEASURES: </b>Outcomes assessed included incident HF hospitalization after V3 and after V5, prevalent frailty at V5, and incident frailty between V5 and visit 6 (V6; 2016-2017; n = 4131). Frailty was assessed using the Fried criteria. Analyses were adjusted for age, gender, race, field center, hypertension, diabetes, smoking status, body mass index, estimated glomerular filtration rate, prevalent coronary heart disease, prevalent atrial fibrillation, and history of myocardial infarction. Mendelian randomization (MR) analysis was performed to assess potential causal effects of candidate proteins on HF and frailty.</p><p><b>RESULTS: </b>A total of 4877 protein aptamers were measured among 10 638 participants at V3 (mean [SD] age, 60 [6] years; 4886 [46%] men). Overall, 286 proteins were associated with incident HF after V3 (822 events; P < 1.0 × 10-5), 83 of which were also associated with incident after V5 (336 events; P < 1.7 × 10-4). Among HF-free participants at V5 (n = 3908; mean [SD] age, 75 [5] years; 1861 [42%] men), 48 of 83 HF-associated proteins were associated with prevalent frailty (223 cases; P < 6.0 × 10-4), 18 of which were also associated with incident frailty at V6 (152 cases; P < 1.0 × 10-3). These proteins enriched fibrosis and inflammation pathways and demonstrated stronger associations with incident HF with preserved ejection fraction (HFpEF) than HF with reduced ejection fraction. All 18 proteins were associated with both prevalent frailty and incident HF in CHS. MR identified potential causal effects of several proteins on frailty and HF.</p><p><b>CONCLUSIONS AND RELEVANCE: </b>In this study, the proteins associated with risk of HF and frailty enrich for pathways related to inflammation and fibrosis as well as risk of HFpEF. Several of these proteins could potentially contribute to the shared pathophysiology of frailty and HF.</p> |
| DOI | 10.1001/jamacardio.2024.1178 |
| Alternate Journal | JAMA Cardiol |
| PubMed ID | 38809565 |
| PubMed Central ID | PMC11137660 |
| Grant List | R01 HL144483 / HL / NHLBI NIH HHS / United States |
ePub date:
24/05